RxDoctor Payments Data

Khurram Liaqat, MD

Interventional Cardiology · Midwest City, OKNPI 1891097358

Payments from drug & device makers

$3,616in general payments, 2019–2025

Across 70 payments — averaging $51.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Terumo Medical Corporation$1K
  • Boston Scientific$972
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$252
  • Abbott$203
  • Johnson & Johnson$125
  • Novartis$113
  • plus $609 from 14 others

What the payments were for

  • Travel & lodging$2,10058%
  • Food & beverage$1,49941%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,616 in reported general payments places this provider in the 30th percentile of 110 interventional cardiology providers in Oklahoma.

See all interventional cardiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$112,823
Medicare patients
627
Services billed
1,569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$25,430
EntrestoSacubitril/Valsartan14$8,566
Ranolazine ErRanolazine16$1,024
Isosorbide Mononitrate ErIsosorbide Mononitrate40$639
Metoprolol Succinate41$594
Atorvastatin Calcium31$338
Nitroglycerin22$268
ClopidogrelClopidogrel Bisulfate35$253
Propranolol Hcl ErPropranolol Hcl18$242
Carvedilol21$224
Rosuvastatin Calcium16$221
Amlodipine Besylate33$140
Losartan Potassium27$133
Furosemide40$132
Lisinopril19$98

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$106$25,43034 claims
NovartisEntresto$113$8,56614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 110 interventional cardiology providers in Oklahoma.

Other interventional cardiology in Midwest City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →